Mutations of KRAS and EGFR are generally mutually exclusive in NSCLC, i.e. most EGFR mutations were existed in KRAS wild-type patients, which might bias the results toward an overestimation of the prognostic and predictive value of KAS mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.